stent News

The rapid discovery of treatments for vascular diseases demands rapid development of device initiatives.

Board-certified in cardiovascular diseases and internal medicine, Dr. Rehman has been an attending cardiologist at SNCH since 2002. He is a fellow of the American College of Cardiology and Society for Cardiovascular Angiography and Intervention.

June 26, 2011. Surat, India. Sahajanand Medical Technologies (SMT) announced today that it has received European CE marking for two Sirolimus eluting coronary stent systems; Supralimus® & Supralimus-Core®

Bharatbook.com has added this latest report "The Drug-Eluting Stent Market Outlook to 2016" to their extensive collection of market research reports. The DES market has seen tremendous growth since the introduction of DES in 2003.

Recently published research from GlobalData, "Interventional Cardiology Devices Global Market Briefing to 2016", is now available at Fast Market Research

Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016

The coronary stents market is dominated by drug-eluting stents, but the market for anti-restenosis has proven dynamic due to many active companies with diverse technologies targeting this area of cardiovascular treatment.

The global coronary stent market faces continued growth, development and competition from a wide range of technology types and competitors. The market is detailed in a new report from MedMarket Diligence.

Vancouver, Canada, June 19th, 2009 - Symbiorph Biomedical Corporation is pleased to announce that it has received CE mark approval for the enhancement in profile and size range of its SYMTREK™ rapid exchange coronary dilatation catheter.

Coronary artery disease treatments have faced a succession of new technology solutions that have led to the large, but now competitive drug-eluting stents market, but the success of developments continues with more challenges and opportunities.

The market for coronary stents worldwide is well established, large and still demonstrating excellent growth, especially with the advent of new technologies from established and hopeful competitors, according to a new report from MedMarket Diligence.

Coronary artery disease is addressed by a range alternative treatment methodologies; percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other options, but stents represent the fastest growing option.